Increased expression of cardiac phosphatases in patients with end-stage heart failure

Journal of Molecular and Cellular Cardiology

Volumn 29, Issue 1, 1997, Pages 265-272

  Neumann, Joachim ^c   Eschenhagen, Thomas ^a,c   Jones, Larry R ^b,c   Linck, Bettina ^c   Schmitz, Wilhelm ^c   Scholz, Hasso ^a,c   Zimmermann, Norbert ^c  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Human heart failure; Phosphatases; Protein phosphorylation

Indexed keywords

INOTROPIC AGENT; MESSENGER RNA; PHOSPHATASE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HEART FAILURE; HUMAN; HUMAN TISSUE; MALE; MEMBRANE VESICLE; PRIORITY JOURNAL;

EID: 0030888810     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1006/jmcc.1996.0271     Document Type: Article

References (32)

1. AHMAD Z, GREEN FJ, SUBUHI HS, WATANABE AM, 1989. Autonomic regulation of type 1 protein phosphatase in cardiac muscle. J Biol Chem 264: 3859-3863.
2. BAI G, ZHANG Z, AMIN J, DEANS-ZIRATTU SA, LEE EYC, 1988. Molecular cloning of a cDNA for the catalytic subunit of rabbit muscle phosphorylase phosphatase. FASEB J 2: 3010-3016.
3. BARTEL S, STEIN B, ESCHENHAGEN T, MENDE U, NEUMANN J, SCHMITZ W, KRAUSE EG, KARCZEWSKI P, SCHOLZ H, 1996. Impaired phosphorylation of phospholamban, troponin I and C-protein in the failing human heart. Mol Cell Biochem (in press).
4. BRADFORD MM, 1976. A rapid and sensitive method for quantitation of microgram qualities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254.
5. BRISTOW MR, GINSBURG R, MINOBE W, CUBICCIOTTI RS, SAGEMAN WS, LURIE K, BILLINGHAM ME, HARRISON DC, STINSON EB, 1982. Decreased catecholamine sensitivity and beta-adrenergic receptor density in failing human hearts. N Engl J Med 307: 205-211.
6. DANIELSEN W, VON DER LEYEN H, MEYER W, NEUMANN J, SCHMITZ W, SCHOLZ H, STARBATTY J, STEIN B, DÖRING V, KALMÁR P, 1989. Basal and isoprenaline-stimulated cAMP content in failing versus nonfailing human cardiac preparations. J Cardiovasc Pharm 14: 171-173.
7. DEPAOLI-ROACH AA, IN-KYUNG P, CEROVSKY V, CSORTOS C, DURBIN SD, KUNTZ MJ, SITIKOV A, TANG PM, VERIN A, ZOLNIEROWICZ S, 1994. Serine/threonine protein phosphatases in the control of cell function. Adv Enzyme Regul 34: 199-224.
8. ERDODI F, CSORTOS C, BOT G, GERGELY P, 1985. Separation of rabbit liver latent and spontaneously active phosphorylase phosphatases by chromatography on heparin-sepharose. Biochem Biophys Res Commun 128: 705-712.
9. ESCHENHAGEN T, MENDE U, NOSE M, SCHMITZ W, SCHOLZ H, HAVERICH A, HIRT S, DÖRING V, KALMAR P, HÖPPNER W, SEITZ HJ, 1992. Increased messenger mRNA levels of the inhibitory G protein alpha subunits Gialpha2 in human end-stage heart failure. Circ Res 70: 688-696.
10. FELDMAN AM, CATES AE, VEAZEY WB, HERSHBERGER RE, BRISTOW MR, BAUGHMAN KL, BAUMGARTNER WA, VAN DOP C, 1988. Increase of the 40,000 mol wt. pertussis toxin substrate (G protein) in the failing human heart. J Clin Invest 82: 189-197.
11. GWATHMEY JK, COPELAS L, MACKINNON R, SCHOEN FJ, FELDMAN MD, GROSSMAN W, MORGAN JP, 1987. Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure. Circ Res 61: 70-76.
12. HERZIG S, PATIL P, NEUMANN J, STASCHEN C-M, YUE DT, 1993. Mechanism of β-adrenergic stimulation of cardiac Ca channels revealed by discrete-time Markov analysis of slow gating. Biophysical J 65: 1599-1612.
13. HERZIG S, MEIER A, PFEIFFER M, NEUMANN J, 1995. Stimulation of protein phosphatases as a mechanism of the muscarinic receptor-mediated inhibition of cardiac L-type calcium channels. Pflügers Arch 429: 531-538.
14. HUNTER T, 1995. Protein kinases and phosphatases: the yin and yang of protein phosphorylation and signalling. Cell 80: 225-236.
15. JONES LR, 1985. Sarcolemmal enzymes mediating β-adrenergic effects in the heart. In: Bronner FA, Shamoo AE, eds, Current Topics in Membranes and Transport; Regulation of Calcium Transport Across Muscle Membranes. Academic Press, New York. 11-41.
16. 2+-ATPaSe in failing and nonfailing human hearts. Cardiovasc Res 31: 625-632.
17. LINCK B, BOKNIK P, LÜSS H, MÜLLER FU, NACKE P, NEUMANN J, SCHMITZ W, VAHLENSIECK U, 1996b. Effects of cantharidin on force of contraction and phosphatase activity in nonfailing and failing human hearts. Br J Pharmacol 119: 545-550.
18. LUO W, GRUPP IL, HARRER J, PONNIAH S, GRUPP G, DUFFY JJ, DOETSCHMAN T, KRANIAS EG, 1994. Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of β-agonist stimulation. Circ Res 75: 401-409.
19. MACDOUGALL LK, JONES LR, COHEN PK, 1991. Identification of the major protein phosphatases in mammalian cardiac muscle which dephosphorylate phospholamban. Eur J Biochem 196: 725-734.
20. 2+-transporting ATPase, phospholamban and calsequestrin levels in nonfailing and failing human heart. Circulation 90: 653-657.
21. MÜLLER FU, BOKNIK P, HORST A, KNAPP J, LINCK B, SCHMITZ W, VAHLENSIECK U, BÖHM M, DENG MC, SCHELD HH, 1995. cAMP response element binding protein is expressed and phosphorylated in the human heart. Circulation 92: 2041-2043.
22. MUMBY MC, WALTER G, 1993. Protein serine/threonine phosphatases: structure, regulation, and functions in cell growth. Physiol Rev 73: 673-699.
23. i-proteins in heart failure. Lancet 2: 936-937.
24. NEUMANN J, GUPTA RC, SCHMITZ W, SCHOLZ H, NAIRN AC, WATANABE AM, 1991. Evidence for isoproterenol-induced phosphorylation of phosphatase inhibitor-1 in the intact heart. Circ Res 69: 1450-1457.
25. NEUMANN J, BOKNIK P, HERZIG S, GUPTA RC, WATANABE AM, SCHMITZ W, SCHOLZ H, 1993. Evidence for physiological functions of protein phosphatases in the heart. Evaluation with okadaic acid. Am J Physiol 265:H257-H266.
26. NEUMANN J, BOKNIK P, HERZIG S, SCHMITZ W, SCHOLZ H, WIECHEN K, ZIMMERMANN N, 1994. Biochemical and electrophysiological mechanisms of the positive inotropic effects of calyculin A, a protein phosphatase inhibitor. J Pharmacol Exp Ther 271: 535-541.
27. NEUMANN J, HERZIG S, BOKNIK P, APEL M, KASPAREIT G, SCHMITZ W, SCHOLZ H, ZIMMERMANN N, 1995. On the cardiac contractile, biochemical and electrophysiological effects of cantharidin, a phosphatase inhibitor. J Pharmacol Exp Ther 274: 530-539.
28. 2+-ATPase. J Biol Chem 270: 9390-9397.
29. SHENOLIKAR S, NAIRN AC, 1991. Protein phosphatases: recent progress. In: Greengard P, Robison GA, eds, Advances in Second Messenger and Phosphoprotein Research. Raven Press, New York, 1-121.
30. ZHANG Z, DEANS-ZIRATTU S, BROWNER MF, LEE EYC, 1992. Expression of the catalytic subunit of phosphorylase phosphatase (protein phosphatase-1) in Escherichia coli. J Biol Chem 267: 1484-1490.
31. ZIMMERMANN N, BODOR GS, BOKNIK P, GAMS E, JONES LR, NEUMANN J, SCHOLZ H, 1995. Mechanisms of the contractile effects of flosequinoxan. Naunyn-Schmiedeberg's Arch Pharmacol 351: 385-390.
32. ZIMMERMANN N, BOKNIK P, GAMS E, GSELL S, JONES LR, MAAS R, NEUMANN J, SCHOLZ H, 1996. Mechanism of the contractile effects of 2,3-butanedione-monoxime in the mammalian heart. Naunyn-Schmiedeberg's Arch Pharmacol 354: 431-436.